WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting

Regulatory Guidance forDeveloping Technologies.

Our attorneys bring deep healthcare and FDA regulatory knowledge to the questions that arise as technology reshapes how care is delivered, how health data moves, and how products reach the market.

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us
Quick Links
  • Visit our Careers Microsite
  • Find the right attorney
  • Sign in to Neuron

Wilson Sonsini secured a jury trial win for Google in a case alleging misuse of advertising technology.

Click for additional details.
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

  • Attorney Recruiting
  • Professional Staff
  • Contacts

News and Featured Insights

Alerts
Health Reimbursement Signals: CMS Proposes Significant Changes to RPM and RTM Requirements
Alerts
Ninth Circuit Addresses CFAA and Agentic AI Tools in Groundbreaking Decision
Alerts
State Healthcare Transaction Notification Laws: A Growing Risk to Deal Timing and Execution in Healthcare M&A
Leading Matters
Client Highlights
Wilson Sonsini Advises Hadrian on $1.37 Billion Series D
On August 6, 2026, Hadrian, the advanced manufacturing company building highly automated factories for America, announced $1.37 billion in new equity financing to accelerate the buildout of the domestic manufacturing capacity needed to deliver America's most critical defense, aerospace, and industrial systems. The raise values Hadrian at $7.87 billion. Wilson Sonsini Goodrich & Rosati advised Hadrian on the transaction.

The financing will be co-led by WCM Investment Management, Washington Harbour Partners, Valor Equity Partners, 137 Ventures, and Baillie Gifford. JPMorganChase's Strategic Investment Group joined as anchor co-lead, investing through the firm's Security and Resiliency Initiative. The round also included major participation by 1789 Capital, as well as Morgan Stanley Wealth Management, funds managed by Apollo, accounts advised by T. Rowe Price Associates, Inc., CapitalG, Andreessen Horowitz, Founders Fund, Lux Capital, Altimeter, Construct Capital, and existing investors.

The Wilson Sonsini team that advised Hadrian on the transaction was led by partners Rezwan Pavri and Colin Conklin. The team also included:

Corporate
Jackie Jung
Andrew Lu
Nara Jo
Mary Cruz
Learn More
Alerts
Wilson Sonsini Advises Cylinder Health on $105 Million Acquisition by Hinge Health
On August 4, 2026, Hinge Health, a digital healthcare company, announced that it has signed a definitive agreement to acquire Cylinder Health, a leader in virtual-first digestive healthcare, for $105 million in cash consideration. Wilson Sonsini Goodrich & Rosati advised Cylinder Health on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises AiDASH on $350 Million Acquisition by Schneider Electric
On July 30, 2026, Schneider Electric, a global energy technology company, announced it has entered a definitive agreement to acquire AiDASH, a cloud-native software company that provides AI-driven vegetation, asset, and climate risk intelligence to utilities and other critical infrastructure operators, in an all-cash transaction with implied enterprise value of $350 million. Wilson Sonsini Goodrich & Rosati is advising AiDASH on the transaction.
Learn More
Client Highlights
Firm Advises DISA Technologies on Launch of DISA Uranium Corporation
On August 4, 2026, DISA® Technologies, a uranium recovery and production company, announced the formation of DISA Uranium™ Corporation, a new American company built to recover and produce domestic uranium and remediate the nation's legacy uranium sites. In connection with its launch, DISA Uranium has entered into a definitive agreement to acquire IsoEnergy's Utah uranium portfolio of permitted, past-producing mines and projects—giving DISA Uranium a scaled conventional resource base to pair with its proprietary processing technology and the only U.S. Nuclear Regulatory Commission license of its kind. Wilson Sonsini Goodrich & Rosati advised DISA on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Discovery Loop on Launch and Initial Funding
On August 5, 2026, a founding team comprised of some of the world’s leading experts in artificial intelligence and distributed computing—Jeff Dean, Sanjay Ghemawat, Quoc Le, and Oriol Vinyals (alphabetical)—announced the launch of Discovery Loop, Inc., a Delaware public benefit corporation. Discovery Loop’s initial funding round is being co-led by Radical Ventures and Khosla Ventures, with participation from Lightspeed, Kleiner Perkins, Doerr Capital, and Alphabet. Wilson Sonsini Goodrich & Rosati is advising Discovery Loop on its launch and the financing.

The company aims to dramatically accelerate technological and scientific progress by automating complex science and engineering tasks. Specifically, it is developing advanced AI systems that leverage massive computational scale to fundamentally transform the speed and efficiency of innovation by automating complete experimental loops. In conjunction with its launch, Discovery Loop has established a long-term partnership with Alphabet for cloud and compute resources.

The Wilson Sonsini team advising Discovery Loop on its launch and initial financing includes Lang Liu, Barath Chari, Alyssa Worsham, Richa Sharma, Sunny Kumar, Will Andrews, MJ Han, Jing Xu, Robert Deng, Jason Choi, and Patrick Begian.

For more information, please see coverage in The Wall Street Journal, The New York Times, and Wired.
Learn More
Client Highlights
Wilson Sonsini Advises Rambus on Accelerated Share Repurchase Program
On August 5, 2026, Rambus Inc., a provider of industry-leading chips and silicon IP for data center and artificial intelligence (AI) infrastructure, announced that it initiated an accelerated share repurchase program with Mizuho Markets Americas LLC to repurchase an aggregate of $100 million of its common stock. Wilson Sonsini Goodrich & Rosati is representing Rambus in the transaction.
Learn More
See More Leading Matters
The Life Sciences Report – June 2026

This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.

Read More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.